( OTC-PINK:ESALY )

News from Morphotek, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Oct 03, 2016, 09:00 ET Morphotek and Eurofarma Laboratórios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it signed an exclusive licensing agreement with Eurofarma...


Sep 13, 2016, 10:00 ET Morphotek Announces Sponsored Research Agreement With Fox Chase Cancer Center To Study Immunosuppressive Effects Of Tumor Shed Antigens To Improve Future Patient Therapies

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a Sponsored Research Agreement (SRA) with Fox Chase...


Feb 03, 2016, 09:00 ET Morphotek Announces Collaboration with Mayo Clinic to Apply Its Folate Receptor Alpha Diagnostic Assays in a Phase II Clinical Trial in Triple-Negative Breast Cancer

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it is collaborating with researchers Keith L. Knutson, Ph.D. in the...


Dec 16, 2015, 09:00 ET Morphotek®, Inc. Announces An Agreement With Biocare Medical, LLC To Develop And Commercialize A Diagnostic Kit For Detection Of Mesothelin In Malignant Tissues

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a second collaboration and license agreement with...


Dec 07, 2015, 09:00 ET Morphotek Announces Phase 1 Results From MORAb-022-001 Trial In Healthy Subjects And Patients With Mild-To-Moderate Rheumatoid Arthritis

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today results from Study MORAb-022-001, a single-dose, dose-ascending,...


Dec 03, 2015, 09:00 ET Morphotek Announces Collaboration Agreement With University Of Wisconsin-Madison To Study The Immunosuppressive Effects Of CA125 Tumor Antigen On Immune-Based Therapies For Ovarian Cancer

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a collaborative research agreement with University of...


Nov 18, 2015, 09:00 ET Morphotek®, Inc. Announces Initiation Of Amatuximab Study In First-Line, Unresectable, Malignant Pleural Mesothelioma Patients

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in the randomized, double-blind...


Nov 17, 2015, 09:00 ET Morphotek Announces Collaboration Agreement With University of Gothenburg To Develop Farletuzumab, An Investigational Anti-Folate Receptor Alpha Monoclonal Antibody, For Alpha-Particle Radioimmunotherapy In Ovarian Cancer

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into an agreement with the Targeted Alpha Therapy Group...


Nov 09, 2015, 09:00 ET Morphotek®, Inc. Announces A License Agreement With Blaze Bioscience, Inc. For The Development Of Novel Oncology Imaging Technology

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Blaze Bioscience, Inc. of...


Oct 26, 2015, 09:00 ET Morphotek®, Inc. Presents Preclinical Findings At ESGO 19 On The Potential Immunosuppressive Effects Of The CA125 Tumor Antigen On Farletuzumab, An Investigational Anti-Folate Receptor Alpha Antibody

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has presented preclinical data showing the immunosuppressive...


Oct 09, 2013, 09:05 ET Morphotek, Inc. Announces Initiation Of A New MORAb-004 Phase I Study In Pediatric Patients With Relapsed/Refractory Solid Tumors

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Children's Oncology Group (COG) has opened enrollment in a Phase 1...


Jun 25, 2013, 09:30 ET Morphotek, Inc. Announces Initiation Of A Phase I Study For MORAb-066

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened...


Aug 27, 2012, 09:00 ET Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Metastatic Soft Tissue Sarcoma

 Morphotek®, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004...


Jan 10, 2012, 09:00 ET Morphotek Enters Into Agreements With Fox Chase Cancer Center to Acquire Clinical Samples for the Development and Validation of Companion Diagnostic Kits

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into two agreements with Fox Chase Cancer Center ("Fox...


Jun 28, 2011, 09:00 ET Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center phase II study of farletuzumab in...


Jun 27, 2011, 09:00 ET Morphotek, Inc. Employees Collect Nearly 9,000 Pounds of Food for Local Families

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has successfully completed a campaign to collect 8,792 pounds of food...


Jun 08, 2011, 09:00 ET Morphotek, Inc. Announces That Two Investigational Drugs Have Received Orphan Drug Designations

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted orphan...


Jun 02, 2011, 09:00 ET Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, phase II study of MORAb-004 for the...


Apr 12, 2011, 09:00 ET Morphotek Receives Grant to Support Development of Therapeutic Antibodies against Biowarfare Agents

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the company has received a grant of approximately $947,000 from the United...


Apr 06, 2011, 09:00 ET Morphotek®, Inc. Receives Beacon Award From CancerCare

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it was recently awarded the Beacon Award from CancerCare, a national...


Apr 04, 2011, 21:30 ET Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc.

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has acquired certain assets relating to a proprietary tumor targeting...


Mar 29, 2011, 08:00 ET Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a collaboration and license agreement with Biocare...


Sep 23, 2009, 08:30 ET Morphotek(R), Inc. Awarded Funding to Develop Therapeutic Antibodies Against Potential Biowarfare Toxins

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that it was awarded $843,289 in funding from the National...


Jul 01, 2009, 08:30 ET Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma...


Jun 09, 2009, 09:00 ET Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors

Antibody Targets Endosialin, a Protein Widely Expressed on Tumors and Tumor Blood Vessel Cells Morphotek(R), Inc., a subsidiary of Eisai...